AMPE Ampio Pharmaceuticals Inc.

0.4
-0.01  -2%
Previous Close 0.41
Open 0.46
Price To Book 12.09
Market Cap 56,527,266
Shares 141,707,862
Volume 1,423,822
Short Ratio 69.61
Av. Daily Volume 1,035,056

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated under SPA - noted June 14, 2019.
Ampion
Osteoarthritis of the Knee
Phase 2b data released May 2015 did not meet endpoints
Optina
Diabetic Macula Edema

Latest News

  1. Ampio Pharmaceuticals Announces Closing of $12 Million Public Offering
  2. Ampio Pharmaceuticals Announces Pricing of Public Offering
  3. Ampio Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
  4. Ampio Regulatory and Clinical Update
  5. Ampio Clinical, Regulatory and Corporate Update
  6. Ampio Pharmaceuticals Provides Regulatory Update
  7. Ampio Pharmaceuticals Provides Corporate Update
  8. Ampio Updates Regulatory Status for Ampion
  9. Research Report Identifies Wolverine World Wide, Viking Therapeutics, Ampio Pharmaceuticals, ArcelorMittal, Delphi Technologies, and Unit with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
  10. Ampio Updates Status of Pivotal Clinical Trial of Ampion to be Carried Out Under a SPA
  11. Ampio Updates Regulatory and Publication status for Ampion™
  12. 3 Health Care Stocks Rallying After US Midterms
  13. Ampio Updates Regulatory and Clinical Status for Ampion™
  14. Bragar Eagel & Squire, P.C. is Investigating Certain Officers and Directors of Ampio Pharmaceuticals, Inc. (AMPE) and Encourages AMPE Investors to Contact the Firm
  15. DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Ampio Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm